Hasturk Hatice, Abdallah Rima, Kantarci Alpdogan, Nguyen Daniel, Giordano Nicholas, Hamilton James, Van Dyke Thomas E
From the Department of Applied Oral Sciences, Center for Periodontology, The Forsyth Institute, Cambridge, MA (H.H., A.K., D.N., T.E.V.D.); Department of Biological and Diagnostic Sciences, Beirut Arab University, Beirut, Lebanon (R.A.); Department of Biophysics, Boston University School of Medicine, MA (J.H.); and Department of Biomedical Engineering, Boston University, MA (N.G.).
Arterioscler Thromb Vasc Biol. 2015 May;35(5):1123-33. doi: 10.1161/ATVBAHA.115.305324. Epub 2015 Mar 19.
Epidemiological and recent clinical studies implicate periodontitis as an independent risk factor for cardiovascular disease. Previously, we demonstrated that rabbits with experimental periodontitis and cholesterol diet exhibit more aortic plaque compared with diet alone. We also showed that a proresolution mediator, Resolvin E1 (RvE1), reverses the experimental periodontitis. Here, we determined whether oral/topical application of RvE1 attenuates aortic atherosclerosis induced by both diet and periodontal inflammation.
Thirty-nine rabbits on a 13-week regimen of 0.5% cholesterol diet were included. Periodontitis was induced by Porphyromonas gingivalis in 24 rabbits and 15 rabbits were placed in no-periodontitis groups. Interventions were no-treatment, vehicle, and RvE1 treatment (4 μg/site or 0.4 μg/site) topically applied 3× per week. At 13 weeks, both periodontitis and atherosclerosis were quantified. Atherosclerotic plaques were assessed by Sudan IV staining, histology, and ex vivo MRI. Serum levels of C-reactive protein were evaluated as a measure of systemic inflammation. RvE1, used as an oral/topical agent, significantly diminished atherogenesis and prevented periodontitis (P<0.05). In the absence of periodontal inflammation, oral/topical application of RvE1 resulted in significantly less arterial plaque, a lower intima/media ratio, and decreased inflammatory cell infiltration compared with no-treatment (P<0.001). Local oral RvE1 application significantly reduced systemic levels of C-reactive protein (P<0.05).
The results suggest that oral/topical RvE1 attenuates enhanced atherogenesis induced by periodontitis and prevents vascular inflammation and atherogenesis in the absence of periodontitis. The inhibition of vascular inflammation with endogenous mediators of resolution of inflammation provides a novel approach in the prevention of atherogenic events.
流行病学及近期临床研究表明,牙周炎是心血管疾病的独立危险因素。此前,我们证明,与单纯饮食组相比,患有实验性牙周炎且采用高胆固醇饮食的兔子主动脉斑块更多。我们还表明,一种促消退介质——消退素E1(RvE1)可逆转实验性牙周炎。在此,我们确定口服/局部应用RvE1是否能减轻由饮食和牙周炎症共同诱导的主动脉粥样硬化。
纳入39只接受为期13周的0.5%胆固醇饮食方案的兔子。24只兔子通过牙龈卟啉单胞菌诱导患牙周炎,15只兔子作为非牙周炎组。干预措施包括不治疗、赋形剂对照以及每周3次局部应用RvE1治疗(4μg/部位或0.4μg/部位)。13周时,对牙周炎和动脉粥样硬化进行量化评估。通过苏丹IV染色、组织学检查和离体磁共振成像评估动脉粥样硬化斑块。评估血清C反应蛋白水平作为全身炎症的指标。作为口服/局部用药的RvE1显著减少了动脉粥样硬化的发生并预防了牙周炎(P<0.05)。在无牙周炎症的情况下,与不治疗相比,口服/局部应用RvE1导致动脉斑块显著减少、内膜/中膜比值降低以及炎症细胞浸润减少(P<0.001)。局部口服RvE1显著降低了全身C反应蛋白水平(P<0.05)。
结果表明,口服/局部应用RvE1可减轻由牙周炎诱导的动脉粥样硬化的增强,并在无牙周炎的情况下预防血管炎症和动脉粥样硬化的发生。利用炎症消退内源性介质抑制血管炎症为预防动脉粥样硬化事件提供了一种新方法。